AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01113671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: includes inactive Ingredients
Study NCT02719314 — intervention group
Intervention type: DRUG
Intervention: Glucocorticoid treatment
Description: Glucocorticoid treatment
Study NCT00607061 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample collection
Description: Blood of the umbilical cord will be collected after delivery. A mother blood sample will be also collected in the few hours preceding delivery to determine glutathione and cysteine concentrations.
Study NCT02113410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit 'N' Fit Chair Yoga (SNFCY)
Description: Experimental: Sit 'N' Fit Chair Yoga - a twice-weekly, 8-week yoga program of 45-minute sessions. Active Comparator: Health Education Program (HEP), a twice-weekly, 8-week program of 45-minute sessions
Study NCT02113410 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program (HEP)
Description: Willing and eligible subjects randomized to the Health Education Program (HEP) attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
Study NCT03532399 — intervention group
Intervention type: DRUG
Intervention: Bivalirudin
Description: CPB: Per hospital protocol, bivalirudin 1 mg/kg IV will be administered to the patient 10 minutes prior to the start of CPB along with an infusion of bivalirudin at 2.5 mg/kg/hr. Additional bolus doses of 0.5 to 1 mg/kg will be administered for ACTs less than the specified target (either 2 times baseline ACT or > 400 seconds per the discretion of the patient's providers). 50mg of bivalirudin will be administered to the bypass circuit.~Cardiac Catheterization: Bivalirudin will be administered to the patient as 0.75mg/kg IV bolus followed by a 1.75mg/kg/hr infusion for the length of the procedure. Changes in infusion rate or bolus dosing during the procedure and post-procedure will be at the discretion of the patient's care providers.~ECMO/VAD: Dosing will be informed by the hospital's formulary recommendations(http://online.lexi.com/lco/action/doc/retrieve/docid/chibos_f/6317841), but will ultimately be determined by patient's primary provider.
Study NCT01947153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Free combination
Study NCT01947153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Fixed dose combination
Study NCT01947153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Combination
Study NCT01947153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Free combination
Study NCT02859519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOB015B
Description: MOB015B - Terbinafine hydrochloride (HCl) 10%, topical solution
Study NCT02859519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MOB015B Vehicle
Description: MOB015B Vehicle without the active ingredient Terbinafine
Study NCT02626650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom elicitiation
Description: Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.
Study NCT02626650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom elicitiation
Description: Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.
Study NCT02516956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Description: Participants will consume the assigned breakfast each morning for 7 days. Participants will express a hedonic rating of the breakfast through 7-point Likert Scales before (overview) and after breakfast consumption.
Study NCT02516956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Breakfast consumption
Description: Participants will consume the assigned breakfast each morning for 7 days. Participants will express a hedonic rating of the breakfast through 7-point Likert Scales before (overview) and after breakfast consumption.
Study NCT02516956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood tests
Description: On the third day, participants will be involved in blood tests. Blood will be taken at baseline (fasting), and up to 4 hours after consuming the breakfast. Participants will complete serial visual analog rating scales of hunger and fullness before (fasting) and every 30 minutes up to 4 hours after breakfast consumption.
Study NCT02516956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood tests
Description: On the third day, participants will be involved in blood tests. Blood will be taken at baseline (fasting), and up to 4 hours after consuming the breakfast. Participants will complete serial visual analog rating scales of hunger and fullness before (fasting) and every 30 minutes up to 4 hours after breakfast consumption.
Study NCT02516956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food choices and energy intakes assessments
Description: Following the last blood sample, participants will be given the opportunity to consume food ad libitum from a buffet lunch. Double weighing of food will be set up to evaluate food choices and energy intake of lunch. During the test week, participants will record all foods and beverage on a 7-day food dairy.
Study NCT02516956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food choices and energy intakes assessments
Description: Following the last blood sample, participants will be given the opportunity to consume food ad libitum from a buffet lunch. Double weighing of food will be set up to evaluate food choices and energy intake of lunch. During the test week, participants will record all foods and beverage on a 7-day food dairy.
Study NCT02516956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention tests
Description: On the fourth day, 4 hours after the breakfast consumption and avoid other foods, participants will be involved in attentional test (Mackworth Clock Test for sustained attention and Stroop Test for selective attention).
Study NCT02516956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention tests
Description: On the fourth day, 4 hours after the breakfast consumption and avoid other foods, participants will be involved in attentional test (Mackworth Clock Test for sustained attention and Stroop Test for selective attention).
Study NCT02516956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fRMI tests
Description: On the fifth day, 4 hours after the breakfast consumption and avoid other foods, participants will focus on a set of photographs (stimuli will be randomly choose from three categories of pictures including food, nonfood, and blurred baseline images) during an fMRI brain scan procedure to scan brain activation responses
Study NCT02516956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fRMI tests
Description: On the fifth day, 4 hours after the breakfast consumption and avoid other foods, participants will focus on a set of photographs (stimuli will be randomly choose from three categories of pictures including food, nonfood, and blurred baseline images) during an fMRI brain scan procedure to scan brain activation responses
Study NCT01380288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivastigmine patch
Description: rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks
Study NCT00661453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid and Levocarnitine
Description: Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
Study NCT03620383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical Heat
Description: Warm heat pack applied topically in participant hand.
Study NCT04544163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate- Fentanyl
Description: drug administration before intubation
Study NCT04544163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 4Mcg/kg
Description: drug administration with induction of anesthesia
Study NCT04544163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 2Mcg/kg
Description: drug administration with induction of anesthesia
Study NCT04544163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 2Mcg/kg
Description: drug administration with induction of anesthesia
Study NCT04544163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg/kg
Description: drug administaration 90 sec before intubation
Study NCT03447106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparotomy
Description: This is a kind of traditional surgical method.
Study NCT03447106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic
Description: laparoscopic surgery
Study NCT03447106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic
Description: the Da Vinci robot assisted gastric resection
Study NCT02301845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diatoms Shells
Description: Instillation of suspended diatom shells - 10 mg q12h
Study NCT03888326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1x1 anodal tDCS
Description: 20 minutes of 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
Study NCT03888326 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
Study NCT03888326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation
Description: 10 days of robotic rehabilitation targeted at proprioception. Therapy is conducted for 1 hour each day for 10 consecutive days (excluding weekends), in combination with either anodal or sham tDCS.
Study NCT03888326 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Robotic Rehabilitation
Description: 10 days of robotic rehabilitation targeted at proprioception. Therapy is conducted for 1 hour each day for 10 consecutive days (excluding weekends), in combination with either anodal or sham tDCS.
Study NCT01638403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).~Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
Study NCT01638403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigil
Description: Modafinil is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~Modafinil tablet at 100 mg are enclosed in gelatine capsules. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
Study NCT01638403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: palcebo
Description: placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
Study NCT02362425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Study NCT02362425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03564834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: Patients will receive laparoscopic gastrectomy within one week after randomization.
Study NCT03564834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: Patients will receive open gastrectomy within one week after randomization.
Study NCT01313221 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: Administered by subcutaneous injection
Study NCT01313221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Administered by subcutaneous injection
Study NCT01313221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical agents
Description: Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~* hydrocortisone 2.5%~* betamethasone valerate 0.1%~* betamethasone dipropionate 0.05%~* clobetasol 0.05%~* calcitriol~* calcipotriol plus betamethsone dipropionate 0.05%
Study NCT01013389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actifuse ABX
Description: bone substitute used for posterolateral instrumented lumbar fusion with interbody fusion
Study NCT01013389 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INFUSE, plus master granules (MGG)
Description: bone substitute in posterolateral instrumented lumbar fusion with interbody fusion
Study NCT02105649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercise + Electrical stimulation of calf muscle
Study NCT02105649 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: selected physical therapy program
Study NCT02105649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy program
Study NCT02298049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Satiated / Pre-meal
Description: All participants were scanned before and after not being fed (pre-meal), and before and after being given a satiating lunch (satiated).
Study NCT02298049 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study NCT00875277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102 cream
Study NCT00875277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 29102 Cream Vehicle
Study NCT00875277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Dipropionate Cream
Study NCT00875277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102 Plus Calcipotriol Cream
Study NCT00875277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102 Plus Betamethasone Dipropionate
Study NCT00875277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet® Ointment
Study NCT03354910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: House Call
Description: 60 to 90 minute home based educational intervention which will be administered by a health educator.
Study NCT03354910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: House Call
Description: 60 to 90 minute home based educational intervention which will be administered by a health educator.
Study NCT03354910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentorship
Description: A National Kidney Foundation Peer Mentor will be assigned to the participant to provide contact and support to study participants.
Study NCT02909309 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: JAWAC system + Capnoline + Spo2
Description: measure mandibular mouvements + etCO2 + pulse oxymetry, respectively
Study NCT03104283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: take apatinib orally until disease progression or appearance of unbearable toxicity
Study NCT00995384 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT Scan
Description: Cardiac CT with special attention to valves in Endocarditis patients.
Study NCT06456086 — intervention group
Intervention type: BIOLOGICAL
Intervention: stimulation with EB virus
Description: stimulation with EB virus
Study NCT03626831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab Prefilled Syringe
Description: Injection of study drug
Study NCT03626831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Injection of placebo
Study NCT01006616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin
Description: Navarixin 10 mg and 30 mg capsules
Study NCT01006616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to navarixin capsules
Study NCT01006616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to navarixin capsules
Study NCT01006616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic
Study NCT01006616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic
Study NCT03569605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help
Description: Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
Study NCT03569605 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group with the addition of behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
Study NCT02947841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternating stimulation
Description: Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.
Study NCT02947841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control cohort will receive Setting A but Setting B will be identical to Setting A.
Study NCT03903835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide Oral Capsule
Description: Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
Study NCT03903835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Oral Capsule
Description: Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
Study NCT03903835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Oral Tablet
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Study NCT03903835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Oral Tablet
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Study NCT03903835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x \[GFR ml/min + 25\].
Study NCT03903835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel 60 mg Solution for Injection
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Study NCT03903835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel Injectable Solution
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Study NCT03903835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel Injectable Solution
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Study NCT03903835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radium Chloride Ra-223
Description: Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Study NCT03903835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib plus Abiraterone acetate plus Prednisone
Description: Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.